The homework was easy. As I've stated before, there is a company that has done a GVHD P2 trial with the FDA and that company is listed on the ASX. You wouldn't of heard of them. FYI, that company has an office in the US (for a very good reason).
Aren't the T20s of CYP remotely interested about how they are going to deliver the GVHD P2 FDA promise that they have been banging on about and kicking the can down the road for YEARS?
Wasa has put CYP management on IGNORE! You have also?
I stick by my comments. And as you know, I have been correct for YEARS.
Mark it down. Again. No office. No trial. No money. No chance. You want me to be wrong, but I've been right about this for years and I continue to be right. Your confusion comes from listening to the CYP management that CONTINUES to make and break 'expected by' dates. The penny hasn't dropped - the latest is 'months away' even though in Jan 2023 it was labelled as 'up to 12 months after approval' which means May 2023. They are prepping to miss there 'expected by' date again.
If you can get your management to deliver of the commencement of this trial that has been promised for YEARS, you will be able to take me to task. Easily done!!! Ha ha ha freaking ha ha ha. Best of British.
All IMO. And the exact opposite opinion of Hector. And it burns her terribly.
Toight. like a Tiger.
Are FDA trials expensive?
BTW, the CYP article of Jan 2023 is telling you they need to have an office in the USA. You don't realise this? And it's clear they don't have the money to do that. Hail Mary, full of grace..........
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)